Literature DB >> 7737712

Different effects of fosinopril and atenolol on wave reflections in hypertensive patients.

C H Chen1, C T Ting, S J Lin, T L Hsu, F C Yin, C O Siu, P Chou, S P Wang, M S Chang.   

Abstract

We conducted this study to compare the effects of fosinopril versus atenolol on peripheral blood pressure, central arterial wave reflection, and left ventricular mass in a group of patients with essential hypertension. We conducted a double-blind, randomized trial of fosinopril and atenolol in 79 hypertensive patients (52 men, 27 women; mean age, 45.8 +/- 8.5 years; range, 30 to 68 years). Carotid pressure waveforms were recorded noninvasively by applanation tonometry with a Millar micromanometer-tipped probe. The extent of wave reflection was estimated by the augmentation index defined as the ratio of the amplitude of pressure wave above its systolic shoulder to the pulse pressure. The augmentation index, left ventricular mass index by two-dimensional echocardiography, and 24-hour ambulatory blood pressures were determined before and after 8 weeks of daily treatment with fosinopril (10 to 20 mg) or atenolol (50 to 100 mg) with or without diuretics and compared with those values in 79 normotensive control subjects. After 8 weeks of treatment, both drugs lowered 24-hour ambulatory peripheral systolic and diastolic pressures into the normal range to a similar extent (fosinopril, -18/-13 mm Hg; atenolol, -23/-17 mm Hg, both P = NS). On the other hand, whereas the elevated augmentation index in hypertensive patients compared with normotensive subjects (16 +/- 11% versus 10 +/- 8%) was completely normalized by fosinopril (-9.3 +/- 9.8%, P < or = .002), it was lowered by atenolol (-4.8 +/- 8.9%, P < .002) but to a significantly smaller extent (fosinopril versus atenolol effect, P = .04).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7737712     DOI: 10.1161/01.hyp.25.5.1034

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  33 in total

Review 1.  Pulse wave analysis.

Authors:  M F O'Rourke; A Pauca; X J Jiang
Journal:  Br J Clin Pharmacol       Date:  2001-06       Impact factor: 4.335

Review 2.  Diastolic pressure, systolic pressure, or pulse pressure?

Authors:  C Vlachopoulos; M O'Rourke
Journal:  Curr Hypertens Rep       Date:  2000-06       Impact factor: 5.369

3.  Increased arterial wave reflection may predispose syncopal attacks.

Authors:  C H Chen; H H Hu; Y P Lin; C M Chern; T L Hsu; P Y Ding
Journal:  Clin Cardiol       Date:  2000-11       Impact factor: 2.882

4.  Mechanical properties of normal and diseased cerebrovascular system.

Authors:  Ali P Ebrahimi
Journal:  J Vasc Interv Neurol       Date:  2009-04

Review 5.  Meta-analysis of the comparative effects of different classes of antihypertensive agents on brachial and central systolic blood pressure, and augmentation index.

Authors:  Charlotte H Manisty; Alun D Hughes
Journal:  Br J Clin Pharmacol       Date:  2013-01       Impact factor: 4.335

Review 6.  Impact of Antihypertensive Agents on Central Systolic Blood Pressure and Augmentation Index: A Meta-Analysis.

Authors:  Tracey J McGaughey; Emily A Fletcher; Sachin A Shah
Journal:  Am J Hypertens       Date:  2015-08-19       Impact factor: 2.689

Review 7.  The latest generation of beta-blockers: new pharmacologic properties.

Authors:  Michala E Pedersen; John R Cockcroft
Journal:  Curr Hypertens Rep       Date:  2006-08       Impact factor: 5.369

Review 8.  Ageing and vascular ageing.

Authors:  B Jani; C Rajkumar
Journal:  Postgrad Med J       Date:  2006-06       Impact factor: 2.401

Review 9.  Treatment of isolated systolic hypertension.

Authors:  Gordon S Stokes
Journal:  Curr Hypertens Rep       Date:  2006-10       Impact factor: 5.369

Review 10.  Renal sympathetic denervation: applications in hypertension and beyond.

Authors:  Michael Böhm; Dominik Linz; Daniel Urban; Felix Mahfoud; Christian Ukena
Journal:  Nat Rev Cardiol       Date:  2013-06-18       Impact factor: 32.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.